Previous 10 | Next 10 |
Company conference call and webcast at 4:30 PM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ ), a highly differentiated, multi-product, commercial-stage medical device company today announced that the companies will host a business update conference call on Tuesday, March 29, 202...
Company conference call and webcast at 4:30 PM EDT Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the ...
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dr. Lishan Aklog, Chairman and CEO, ...
Lucid Diagnostics' (LUCD -4.7%) unit LucidDx Labs acquired certain licenses and other related assets from ResearchDx to operate its own new CLIA-certified, CAP-accredited clinical laboratory located in Lake Forest, California. Lucid — which is a majority-owned subsidiary of P...
New wholly owned Lucid subsidiary now performing EsoGuard ® Esophageal DNA Test in its own new state-of-the-art CLIA-certified, CAP-accredited clinical laboratory Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention...
PAVmed (NASDAQ:PAVM) appointed Shaun O'Neil as EVP & COO, overseeing diverse corporate operations and commercial activities across the company and its subsidiaries. Mr. O’Neil has served as the company's Chief Commercial Officer and EVP, Business Development since joining...
PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), today announced the appoin...
PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) , today announced the a...
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dr. Lishan Aklog, Chairman and CEO, will...
MDJM (NASDAQ:MDJH) +64%. The OLB Group OLB +25% reports $1.35B in transaction value post CBD Merchants acquisition. Advanced Micro Devices AMD +13% on Q4 results. Xilinx (NASDAQ:XLNX) +12%. Capri Holdings CPRI +12% on Q3 results. IceCure Medical (NASDAQ:ICCM) +11%. Arrival...
News, Short Squeeze, Breakout and More Instantly...
PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024 PR Newswire Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , July 30, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "C...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024 PR Newswire Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , July 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Luc...
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...